Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal
A mutual recognition agreement between the UK and EU on equivalence of regulatory procedures and processes could provide pharmaceutical companies with some stability and continuity post-Brexit – and save them some money.
You may also be interested in...
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.
Europe is becoming less competitive in the advanced therapy space, something that is reflected in the number of EU ATMP marketing authorization withdrawals, speakers said at an event organized by the Alliance for Regenerative Medicine.